skip to Main Content

New Blood Test in Development to Detect Pancreatic Cancer Early

Newsfeed image, light gray text on dark gray background

Key Takeaways

  • A 31-biomarker blood test could distinguish patients with early-stage pancreatic ductal adenocarcinoma (PDAC) from healthy persons with a high degree of accuracy.
  • Individually weak serum biomarkers, such as CEA and CA 19-9, were combined into a robust screening assay.

Why This Matters

  • About 65% of patients with PDAC present late with unresectable disease.
  • An accurate, cost-effective blood test to catch early, asymptomatic disease could substantially increase the number of patients eligible for curative surgery. Read more . . . .


Back To Top